Molecular mechanisms of chondrosarcoma metastasis

BioMedicine (Netherlands)

Volumn 2, Issue 3, 2012, Pages 92-98

  Tang, Chih Hsin ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chondrosarcoma; ICAM 1; Integrin; Migration; MMP

Indexed keywords

ALPHA2 INTEGRIN; ALPHA5 INTEGRIN; BETA1 INTEGRIN; BETA3 INTEGRIN; CD51 ANTIGEN; COLLAGENASE 3; CYCLOOXYGENASE 2; GELATINASE A; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN;

AMINO ACID SEQUENCE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CHONDROSARCOMA; HUMAN; INTRACELLULAR SIGNALING; METASTASIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; STRUCTURE ACTIVITY RELATION; UPREGULATION;

EID: 84866481187     PISSN: 22118020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomed.2012.01.001     Document Type: Review

References (70)

1. Lee F.Y., Mankin H.J., Fondren G., Gebhardt M.C., Springfield D.S., Rosenberg A.E., et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999, 81(3):326-338.
2. Daugaard S., Myhre-Jensen O., Schiodt T., Jurik A.G., Keller J., Mouridsen H.T., et al. Clinical and histopathological prognostic factors in chondrosarcomas. Sarcoma 1997, 1(1):47-54.
3. Sandberg A.A. Genetics of chondrosarcoma and related tumors. Curr Opin Oncol 2004, 16(4):342-354.
4. Dorfman H.D., Czerniak B. Bone cancers. Cancer 1995, 75(1 Suppl):203-210.
5. Korten A.G., ter Berg H.J., Spincemaille G.H., van der Laan R.T., Van de Wel A.M. Intracranial chondrosarcoma: review of the literature and report of 15 cases. J Neurol Neurosurg Psychiatry 1998, 65(1):88-92.
6. Watters G.W., Brookes G.B. Chondrosarcoma of the temporal bone. Clin Otolaryngol Allied Sci 1995, 20(1):53-58.
7. Bloch O.G., Jian B.J., Yang I., Han S.J., Aranda D., Ahn B.J., et al. Cranial chondrosarcoma and recurrence. Skull Base 2010, 20(3):149-156.
8. Rizzo M., Ghert M.A., Harrelson J.M., Scully S.P. Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome. Clin Orthop Relat Res 2001 Oct, (391):224-233.
9. Pramesh C.S., Deshpande M.S., Pardiwala D.N., Agarwal M.G., Puri A. Core needle biopsy for bone tumours. Eur J Surg Oncol 2001, 27(7):668-671.
10. York J.E., Berk R.H., Fuller G.N., Rao J.S., Abi-Said D., Wildrick D.M., et al. Chondrosarcoma of the spine: 1954 to 1997. J Neurosurg 1999, 90(1 Suppl):73-78.
11. Yuan J., Dutton C.M., Scully S.P. RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res 2005, 23(6):1467-1474.
12. Fong Y.C., Yang W.H., Hsu S.F., Hsu H.C., Tseng K.F., Hsu C.J., et al. 2-methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. J Orthop Res 2007, 25(8):1106-1114.
13. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147(2):275-292.
14. Bloch O., Sughrue M.E., Mills S.A., Parsa A.T. Signaling pathways in cranial chondrosarcoma: potential molecular targets for directed chemotherapy. J Clin Neurosci 2011, 18(7):881-885.
15. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001, 411(6835):375-379.
16. Liotta L.A., Kohn E. Cancer invasion and metastases. JAMA 1990, 263(8):1123-1126.
17. Zetter B.R. The cellular basis of site-specific tumor metastasis. N Engl J Med 1990, 322(9):605-612.
18. Humphries M.J. Integrin structure. Biochem Soc Trans 2000, 28(4):311-339.
19. Stupack D.G. The biology of integrins. Oncology 2007, 21(9 Suppl. 3):6-12. Williston Park.
20. Luo B.H., Carman C.V., Springer T.A. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007, 25:619-647.
21. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110(6):673-687.
22. White D.E., Kurpios N.A., Zuo D., Hassell J.A., Blaess S., Mueller U., et al. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004, 6(2):159-170.
23. Heyder C., Gloria-Maercker E., Hatzmann W., Niggemann B., Zanker K.S., Dittmar T. Role of the beta1-integrin subunit in the adhesion, extravasation and migration of T24 human bladder carcinoma cells. Clin Exp Metastasis 2005, 22(2):99-106.
24. Seales E.C., Jurado G.A., Brunson B.A., Wakefield J.K., Frost A.R., Bellis S.L. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res 2005, 65(11):4645-4652.
25. Takenaka K., Shibuya M., Takeda Y., Hibino S., Gemma A., Ono Y., et al. Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line. Int J Oncol 2000, 17(6):1187-1194.
26. Yeh Y.Y., Chiao C.C., Kuo W.Y., Hsiao Y.C., Chen Y.J., Wei Y.Y., et al. TGF-beta1 increases motility and alphavbeta3 integrin up-regulation via PI3K, Akt and NF-kappaB-dependent pathway in human chondrosarcoma cells. Biochem Pharmacol 2008, 75(6):1292-1301.
27. Lai T.H., Fong Y.C., Fu W.M., Yang R.S., Tang C.H. Stromal cell-derived factor-1 increase alphavbeta3 integrin expression and invasion in human chondrosarcoma cells. J Cell Physiol 2009, 218(2):334-342.
28. Yang S.N., Chen H.T., Tsou H.K., Huang C.Y., Yang W.H., Su C.M., et al. Leptin enhances cell migration in human chondrosarcoma cells through OBRl leptin receptor. Carcinogenesis 2009, 30(4):566-574.
29. Su C.M., Lu D.Y., Hsu C.J., Chen H.T., Huang C.Y., Yang W.H., et al. Glial cell-derived neurotrophic factor increases migration of human chondrosarcoma cells via ERK and NF-kappaB pathways. J Cell Physiol 2009, 220(2):499-507.
30. Hou C.H., Yang R.S., Hou S.M., Tang C.H. TNF-alpha increases alphavbeta3 integrin expression and migration in human chondrosarcoma cells. J Cell Physiol 2011, 226(3):792-799.
31. Lee C.Y., Huang C.Y., Chen M.Y., Lin C.Y., Hsu H.C., Tang C.H. IL-8 increases integrin expression and cell motility in human chondrosarcoma cells. J Cell Biochem 2011, 112(9):2549-2557.
32. Tan T.W., Yang W.H., Lin Y.T., Hsu S.F., Li T.M., Kao S.T., et al. Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells. Carcinogenesis 2009, 30(2):258-268.
33. Tan T.W., Lai C.H., Huang C.Y., Yang W.H., Chen H.T., Hsu H.C., et al. CTGF enhances migration and MMP-13 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Biochem 2009, 107(2):345-356.
34. Chen Y.J., Wei Y.Y., Chen H.T., Fong Y.C., Hsu C.J., Tsai C.H., et al. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol 2009, 221(1):98-108.
35. Tzeng H.E., Chen J.C., Tsai C.H., Kuo C.C., Hsu H.C., Hwang W.L., et al. CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin-dependent pathway. J Cell Physiol 2011, 226(12):3181-3189.
36. Liu J.F., Fong Y.C., Chang C.S., Huang C.Y., Chen H.T., Yang W.H., et al. Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol Cancer 2010, 9:43.
37. Yang W.H., Chang J.T., Hsu S.F., Li T.M., Cho D.Y., Huang C.Y., et al. Bradykinin enhances cell migration in human chondrosarcoma cells through BK receptor signaling pathways. J Cell Biochem 2010, 109(1):82-92.
38. Chiu Y.C., Shieh D.C., Tong K.M., Chen C.P., Huang K.C., Chen P.C., et al. Involvement of AdipoR receptor in adiponectin-induced motility and alpha2beta1 integrin upregulation in human chondrosarcoma cells. Carcinogenesis 2009, 30(10):1651-1659.
39. Wu C.M., Li T.M., Hsu S.F., Su Y.C., Kao S.T., Fong Y.C., et al. IGF-I enhances alpha5beta1 integrin expression and cell motility in human chondrosarcoma cells. J Cell Physiol 2011, 226(12):3270-3277.
40. Gross J., Lapiere C.M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A 1962, 48:1014-1022.
41. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. Faseb J 1991, 5(8):2145-2154.
42. Murphy G., Knauper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?. Matrix Biol 1997, 15(8-9):511-518.
43. Bode W., Fernandez-Catalan C., Tschesche H., Grams F., Nagase H., Maskos K. Structural properties of matrix metalloproteinases. Cell Mol Life Sci 1999, 55(4):639-652.
44. Chernov A.V., Sounni N.E., Remacle A.G., Strongin A.Y. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem 2009, 284(19):12727-12734.
45. Pei D., Weiss S.J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995, 375(6528):244-247.
46. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2(3):161-174.
47. Kerkela E., Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 2003, 12(2):109-125.
48. Tsai Y.Y., Chiang C.C., Yeh K.T., Lee H., Cheng Y.W. Effect of TIMP-1 and MMP in pterygium invasion. Invest Ophthalmol Vis Sci 2010, 51(7):3462-3467.
49. Soderstrom M., Aro H.T., Ahonen M., Johansson N., Aho A., Ekfors T., et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. APMIS 2001, 109(4):305-315.
50. Jiang X., Dutton C.M., Qi W.N., Block J.A., Garamszegi N., Scully S.P. siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J Cell Physiol 2005, 202(3):723-730.
51. Chen H.T., Tsou H.K., Tsai C.H., Kuo C.C., Chiang Y.K., Chang C.H., et al. Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway. J Cell Physiol 2010, 223(3):737-745.
52. Hou C.H., Chiang Y.C., Fong Y.C., Tang C.H. WISP-1 increases MMP-2 expression and cell motility in human chondrosarcoma cells. Biochem Pharmacol 2011, 81(11):1286-1295.
53. Tang C.H., Yamamoto A., Lin Y.T., Fong Y.C., Tan T.W. Involvement of matrix metalloproteinase-3 in CCL5/CCR5 pathway of chondrosarcomas metastasis. Biochem Pharmacol 2010, 79(2):209-217.
54. Hou C.H., Hsiao Y.C., Fong Y.C., Tang C.H. Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13. Bone 2009, 44(2):233-242.
55. Tang C.H., Chen C.F., Chen W.M., Fong Y.C. IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells. J Biol Chem 2011, 286(13):11056-11066.
56. Lawson C., Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep 2009, 61(1):22-32.
57. Zimmerman T., Blanco F.J. Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action. Curr Pharm Des 2008, 14(22):2128-2139.
58. Duperray A., Languino L.R., Plescia J., McDowall A., Hogg N., Craig A.G., et al. Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging. J Biol Chem 1997, 272(1):435-441.
59. Georgolios A., Batistatou A., Bonitsis N., Stagikas D., Manolopoulos L., Charalabopoulos K. The role of intercellular adhesion molecule-1 in head and neck cancer. Exp Oncol 2006, 28(4):270-274.
60. Huang W.C., Chan S.T., Yang T.L., Tzeng C.C., Chen C.C. Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel alpha-methylene-gamma-butyrolactone derivatives. Carcinogenesis 2004, 25(10):1925-1934.
61. Rosette C., Roth R.B., Oeth P., Braun A., Kammerer S., Ekblom J., et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 2005, 26(5):943-950.
62. Fong Y.C., Lin C.Y., Su Y.C., Chen W.C., Tsai F.J., Tsai C.H., et al. CCN6 enhances ICAM-1 expression and cell motility in human chondrosarcoma cells. J Cell Physiol 2012, 227(1):223-232.
63. Warner T.D., Mitchell J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. Faseb J 2004, 18(7):790-804.
64. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002, 68-69:165-175.
65. Turini M.E., DuBois R.N. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002, 53:35-57.
66. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995, 55(17):3785-3789.
67. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998, 58(17):3761-3764.
68. Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998, 90(6):455-460.
69. Suzawa T., Miyaura C., Inada M., Maruyama T., Sugimoto Y., Ushikubi F., et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000, 141(4):1554-1559.
70. Watabe A., Sugimoto Y., Honda A., Irie A., Namba T., Negishi M., et al. Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J Biol Chem 1993, 268(27):20175-20178.